JPH0647546B2 - 医薬組成物 - Google Patents
医薬組成物Info
- Publication number
- JPH0647546B2 JPH0647546B2 JP59191390A JP19139084A JPH0647546B2 JP H0647546 B2 JPH0647546 B2 JP H0647546B2 JP 59191390 A JP59191390 A JP 59191390A JP 19139084 A JP19139084 A JP 19139084A JP H0647546 B2 JPH0647546 B2 JP H0647546B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- defibrotide
- acute renal
- renal failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 208000009304 Acute Kidney Injury Diseases 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 208000033626 Renal failure acute Diseases 0.000 claims description 9
- 201000011040 acute kidney failure Diseases 0.000 claims description 9
- 208000012998 acute renal failure Diseases 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 239000006186 oral dosage form Substances 0.000 claims 1
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 abstract description 13
- 229960004120 defibrotide Drugs 0.000 abstract description 13
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 231100000749 chronicity Toxicity 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 206010060860 Neurological symptom Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 201000003126 Anuria Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- -1 urokinase Chemical class 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22856A/83 | 1983-09-12 | ||
| IT22856/83A IT1170215B (it) | 1983-09-12 | 1983-09-12 | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6084224A JPS6084224A (ja) | 1985-05-13 |
| JPH0647546B2 true JPH0647546B2 (ja) | 1994-06-22 |
Family
ID=11201234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59191390A Expired - Lifetime JPH0647546B2 (ja) | 1983-09-12 | 1984-09-12 | 医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4649134A (enExample) |
| EP (1) | EP0137542B1 (enExample) |
| JP (1) | JPH0647546B2 (enExample) |
| AT (1) | ATE65696T1 (enExample) |
| BE (1) | BE900563A (enExample) |
| CH (1) | CH661871A5 (enExample) |
| DE (1) | DE3433329A1 (enExample) |
| IT (1) | IT1170215B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1170214B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per la cura delle arteriopatie periferiche |
| IT1190313B (it) * | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US5223609A (en) * | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1223322B (it) * | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
| IT1231509B (it) * | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| US5624912A (en) * | 1991-08-21 | 1997-04-29 | Burcoglu; Arsinur | Method of treating HIV infection and related secondary infections with defibrotide |
| CA2153778C (en) * | 1993-01-13 | 2004-07-06 | Arsinur Burcoglu | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| HK1044896A1 (zh) * | 1997-04-28 | 2002-11-08 | Burcoglu Arsinur | 治疗hiv感染和与之有关的继发感染的方法 |
| EP1325962A1 (en) * | 2001-12-17 | 2003-07-09 | Gentium S.p.A. | A method for determining the biological activity of defibrotide |
| EP1872787A1 (en) * | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
| WO2009065171A1 (en) | 2007-11-19 | 2009-05-28 | Cochlear Limited | Electrode array for a cochlear implant |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| IT1406068B1 (it) | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
| DK2637672T3 (en) | 2010-11-12 | 2018-10-22 | Gentium S R L | DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD) |
| KR20150044877A (ko) * | 2012-06-22 | 2015-04-27 | 젠티엄 에스피에이 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| RU2766143C2 (ru) * | 2017-07-26 | 2022-02-08 | Джентиум С.Р.Л. | Жидкая композиция дефибротида для лечения и профилактики веноокклюзионной болезни |
| KR20200121780A (ko) * | 2017-08-03 | 2020-10-26 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 높은 농도에서 핵산을 포함하는 제제 |
| BR112020020865A2 (pt) | 2018-04-12 | 2021-01-19 | Jazz Pharmaceuticals, Inc. | Defibrotida para prevenção e tratamento da síndrome de liberação de citocinas e neurotoxicidade associadas à imunodepleção |
| US20230086833A1 (en) | 2020-04-17 | 2023-03-23 | Jazz Pharmaceuticals Ireland Limited | Defibrotide treatment for the prevention of organ rejection and injury |
| TW202308659A (zh) | 2021-05-06 | 2023-03-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB879622A (en) * | 1959-07-13 | 1961-10-11 | Farmaceutici Italia | Steroids |
| DE1202439B (de) * | 1959-11-24 | 1965-10-07 | Cediap Centrale De Destributio | Verfahren zur Herstellung von Praeparaten mit hohem Gehalt an freien Desoxyribonucleinsaeuren aus Fischmilch |
| FR2575M (fr) * | 1962-03-19 | 1964-06-08 | Cediap Centrale De Distrib D A | Procédé de préparation d'un médicament a base d'adn (acide désoxyribonucléique) en milieu vital d'origine et produit nouveau en résultant. |
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
-
1983
- 1983-09-12 IT IT22856/83A patent/IT1170215B/it active
-
1984
- 1984-09-07 CH CH4281/84A patent/CH661871A5/it not_active IP Right Cessation
- 1984-09-07 AT AT84201286T patent/ATE65696T1/de not_active IP Right Cessation
- 1984-09-07 EP EP84201286A patent/EP0137542B1/en not_active Expired - Lifetime
- 1984-09-10 US US06/649,069 patent/US4649134A/en not_active Expired - Fee Related
- 1984-09-11 DE DE19843433329 patent/DE3433329A1/de active Granted
- 1984-09-12 BE BE0/213640A patent/BE900563A/fr not_active IP Right Cessation
- 1984-09-12 JP JP59191390A patent/JPH0647546B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6084224A (ja) | 1985-05-13 |
| EP0137542B1 (en) | 1991-07-31 |
| DE3433329A1 (de) | 1985-03-28 |
| EP0137542A2 (en) | 1985-04-17 |
| CH661871A5 (it) | 1987-08-31 |
| IT8322856A0 (it) | 1983-09-12 |
| EP0137542A3 (en) | 1987-09-02 |
| IT1170215B (it) | 1987-06-03 |
| DE3433329C2 (enExample) | 1993-07-22 |
| BE900563A (fr) | 1985-01-02 |
| US4649134A (en) | 1987-03-10 |
| ATE65696T1 (de) | 1991-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0647546B2 (ja) | 医薬組成物 | |
| Murray | Heparin in thrombosis and embolism | |
| Yolken et al. | Acute fluoride poisoning | |
| Parsons et al. | Salmonella infections of the abdominal aorta | |
| JP2020186241A (ja) | 酸素化コレステロール硫酸塩（ｏｃｓ）の使用 | |
| US4451454A (en) | Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals | |
| Parbhoo et al. | Extracorporeal pig-liver perfusion in treatment of hepatic coma due to fulminant hepatitis | |
| Malpas et al. | Rubidomycin in acute leukaemia in adults | |
| JP6648106B2 (ja) | 自己消化の治療用組成物 | |
| JPH0647545B2 (ja) | 医薬用組成物 | |
| McGuigan | Acute iron poisoning | |
| Ramsbottom et al. | Studies of the effect of metoclopramide and apomorphine on gastric emptying and secretion in man | |
| Jones et al. | Frusemide-induced pancreatitis | |
| US5360790A (en) | Method and formulations for the therapy of acute renal failure | |
| US6720011B1 (en) | Injectable composition for cancer treatment | |
| Murphy et al. | A case of poisoning with mercuric chloride | |
| Naik et al. | Ingestion of formic acid-containing agents--report of three fatal cases | |
| JPH0825885B2 (ja) | 特発性血小板減少性紫斑病治療剤 | |
| Snyder Jr et al. | Fecal retention in children with cystic fibrosis: report of three cases | |
| Miyata et al. | Ischemic colitis in a 33-year-old woman on danazol treatment for endometriosis. | |
| US3193461A (en) | Correcting blood changes with niacin, vitamin a, and riboflavin | |
| HARKINS et al. | Peritonitis due to bile and to liver autolysis | |
| Lavender et al. | Iron intoxication in an adult | |
| Edwards et al. | Effect of two new antisecretory drugs on fluid and electrolyte transport in a patient with secretory diarrhoea. | |
| Lankisch et al. | Acute pancreatitis: treatment |